Learn, Analyse & Invest
only with
only with
+91
Download Orca
Gennex Laboratories Ltd.
Gennex Lab
₹ 0.00
0.00 (0.00)%
NSE
BSE
Healthcare
Small-cap - With a market cap of ₹2.29 Cr.
| EX-Date | Purpose |
|---|---|
| 18 06 2021 | Inter-alia, to consider the following matters: 1.Appointment of Mr. Rakesh Kumar Gupta as a Secretarial Auditor of the Company for the Financial Year 2020-21; 2.Other Business items. This intimation is also being uploaded in the Company website: www.gennexlab.com. We request you to take the above information on record and acknowledge the receipt of the same. |
| 30 06 2021 | Audited Results |
| 13 08 2021 | Quarterly Results |
| 06 09 2021 | A.G.M. & Inter-alia, consider the following matters, among other items of agenda: 1. To decide regarding the conduct of 36th AGM for the year ended March 31, 2021; 2. To Consider the Appointment of Secretarial Auditor for the FY 2021-22; 3. To Consider the Appointment of Cost Auditor for the FY 2021-22. 4. To Consider and Appoint Scrutinizer of the 36th Annual General Meeting in case of Finalisation of the Date of AGM; 5. Other Business items. |
| 13 11 2021 | Quarterly Results |
| 04 01 2022 | Inter-alia, consider the following matters, among other items of agenda: 1. The Company is intending to make Deccan Remedies Limited (Deccan) as our subsidiary by acquire additional 836,165 equity shares i.e., equivalent to 6.73% from the existing Deccan promoter group; 2. Proposing to Appoint Mr. Arihant Baid, Managing Director of the Company in the Board of Deccan to manage the Affairs of Deccan. 3. Other Business items. |
| 14 02 2022 | Quarterly Results |
| 06 04 2022 | Rights Issue & Inter alia, to consider the following matters, among other items of agenda: 1. To Consider the proposal for raising of funds by issuance of equity shares or any other securities, through permissible modes including but not limited to a rights issue, as may be permitted under applicable law and subject to such regulatory/ statutory approvals, as may be 2. Other Business items. |
| 30 05 2022 | Audited Results & Quarterly Results |
| 24 06 2022 | Right Issue of Equity Shares Inter-alia, to consider the following matters: 1. To discuss the further steps of the proposed Rights Issue; 2. Other Business items. |
| 16 07 2022 | Rights Issue Inter-alia , to consider the following matters: 1. To consider and a pprove the Letter of Offer; 2. Fixation of Record Date for Rights Issue; 3 . Determination of Rights Price, No. of shares to be issued and Ratio; 4 . Other Business items. |
| 12 08 2022 | Quarterly Results |
| 06 09 2022 | Inter-alia, consider the following matters: 1. To decide regarding the conduct of 37th AGM for the year ended March 31, 2022; 2. To Consider and Appoint Scrutinizer of the 37th Annual General Meeting in case of Finalisation of the Date of AGM; 3. Other Business items. |
| 26 09 2022 | Inter alia, to consider and approve :- 1. To consider and approve the Call Notice; 2. Fixation of Record Date for the First and Final Call Money; 3. Determination of Call Money period; 4. Other Business items |
| 14 11 2022 | Quarterly Results |
| 14 02 2023 | Quarterly Results |
| 20 04 2023 | Inter alia, to consider the following: 1. To Consider and Appoint Mr. Dinesh Kumar Kejriwal as a Company Secretary & Compliance Officer of the Company. 2.To Consider and Approve the appointment of Mr. Arihant Baid act as Managing Director in the Deccan Remedies Limited, which is a Subsidiary of Gennex Laboratories Limited. |
| 30 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results |
| 06 09 2023 | A.G.M. |
| 14 11 2023 | Quarterly Results |
| 02 12 2023 | Preferential Issue of shares Inter alia, is to consider the following matter, in addition to the items intimated earlier: 1. Fundraising by way of preferential issue To discuss, consider and approve a proposal for raising further capital and to create, offer, issue and allot such number of equity shares and/ or equity linked instruments or securities, including share warrants or otherwise through preferential allotment in accordance with the relevant provisions of applicable law or any combination thereof, in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and all other applicable laws, as may be considered appropriate, subject to such governmental/ statutory/regulatory and other approvals as may be required including the approval of the shareholders of the Company. |
| 14 02 2024 | Quarterly Results |
| 14 11 2024 | Quarterly Results Inter alia, to consider and approve:- 2. Consider the Limited Review Reports of the Statutory Auditor on Standalone and Consolidated Financial Statements for the Quarter and Half-Year ended September 30, 2024; 3. Reconstitution of the Audit Committee of the Company; 4. Reconstitution of the Nomination & Remuneration Committee of the Company; 5. Reconstitution of the Stakeholders Relationship Committee of the Company; 6. Other Business items. |
| 14 02 2025 | Quarterly Results |
| 30 05 2025 | Audited Results |
| 04 09 2025 | A.G.M. |
| 14 11 2025 | Quarterly Results |
| 14 02 2026 | Quarterly Results |
News
